|
1
|
Siegel RL, Miller KD, Fuchs HE and Jemal
A: Cancer statistics. CA Cancer J Clin. 71:7–33. 2021.
|
|
2
|
Park JW, Seo MJ, Cho KS, Kook MC, Jeong
JM, Roh SG, Cho SY, Cheon JH and Kim HK: Smad4 and p53 synergize in
suppressing autochthonous intestinal cancer. Cancer Med.
11:1925–1936. 2022.
|
|
3
|
Villalba M, Evans SR, Vidal-Vanaclocha F
and Calvo A: Role of TGF-β in metastatic colon cancer: It is
finally time for targeted therapy. Cell Tissue Res. 370:29–39.
2017.
|
|
4
|
André T, Shiu KK, Kim TW, Jensen BV,
Jensen LH, Punt C, Smith D, Garcia-Carbonero R, Benavides M, Gibbs
P, et al: Pembrolizumab in microsatellite-instability-high advanced
colorectal cancer. N Engl J Med. 383:2207–2218. 2020.
|
|
5
|
Cremolini C, Loupakis F, Antoniotti C,
Lupi C, Sensi E, Lonardi S, Mezi S, Tomasello G, Ronzoni M,
Zaniboni A, et al: FOLFOXIRI plus bevacizumab versus FOLFIRI plus
bevacizumab as first-line treatment of patients with metastatic
colorectal cancer: updated overall survival and molecular subgroup
analyses of the open-label, phase 3 TRIBE study. Lancet Oncol.
16:1306–1315. 2015.
|
|
6
|
Arnold D, Lueza B, Douillard JY, Peeters
M, Lenz HJ, Venook A, Heinemann V, Van Cutsem E, Pignon JP,
Tabernero J, et al: Prognostic and predictive value of primary
tumour side in patients with RAS wild-type metastatic colorectal
cancer treated with chemotherapy and EGFR-directed antibodies in
six randomized trials. Ann Oncol. 28:1713–1729
|
|
7
|
Togo S, Polanska UM, Horimoto Y and Orimo
A: Carcinoma-associated fibroblasts are a promising therapeutic
target. Cancers (Basel). 5:149–169. 2013.
|
|
8
|
Sahai E, Astsaturov I, Cukierman E,
DeNardo DG, Egeblad M, Evans RM, Fearon D, Greten FR, Hingorani SR,
Hunter T, et al: A framework for advancing our understanding of
cancerassociated fibroblasts. Nat Rev Cancer. 20:174–186. 2020.
|
|
9
|
Czekay RP, Cheon DJ, Samarakoon R, Kutz SM
and Higgins PJ: Cancer-associated fibroblasts: Mechanisms of tumor
progression and novel therapeutic targets. Cancers.
14:12312022.
|
|
10
|
Leroy B, Anderson M and Soussi T: TP53
mutations in human cancer: Database reassessment and prospects for
the next decade. Hum Mutat. 35:672–688. 2014.
|
|
11
|
Hayashi Y, Tsujii M, Kodama T, Akasaka T,
Kondo J, Hikita H, Inoue T, Tsujii Y, Maekawa A, Yoshii S, et al:
p53 functional deficiency in human colon cancer cells promotes
fibroblast-mediated angiogenesis and tumor growth. Carcinogenesis.
37:972–984. 2016.
|
|
12
|
Yoshii S, Hayashi Y, Iijima H, Inoue T,
Kimura K, Sakatani A, Nagai K, Fujinaga T, Hiyama S, Kodama T, et
al: Exosomal microRNAs derived from colon cancer cells promote
tumor progression by suppressing fibroblast TP53 expression. Cancer
Sci. 110:2396–2407. 2019.
|
|
13
|
Tatemoto K, Hosoya M, Habata Y, Fujii R,
Kakegawa T, Zou MX, Kawamata Y, Fukusumi S, Hinuma S, Kitada C, et
al: Isolation and characterization of a novel endogenous peptide
ligand for the human APJ receptor. Biochem Biophys Res Commun.
251:471–476. 1998.
|
|
14
|
Masoumi J, Jafarzadeh A, Khorramdelazad H,
Abbasloui M, Abdolalizadeh J and Jamali N: Role of apelin/APJ axis
in cancer development and progression. Adv Med Sci. 65:202–213.
2020.
|
|
15
|
Narayanan S, Harris DL, Maitra R and
Runyon SP: Regulation of the apelinergic system and its potential
in cardiovascular disease: Peptides and small molecules as tools
for discovery. J Med Chem. 58:7913–7927. 2015.
|
|
16
|
Nagpal V, Rai R, Place AT, Murphy SB,
Verma SK, Ghosh AK and Vaughan DE: MiR-125b is critical for
fibroblast-to-myofibroblast transition and cardiac fibrosis.
Circulation. 133:291–301. 2016.
|
|
17
|
Kim J: Apelin-APJ signaling: A potential
therapeutic target for pulmonary arterial hypertension. Mol Cells.
37:196–201. 2014.
|
|
18
|
Yokoyama Y, Sekiguchi A, Fujiwara C,
Uchiyama A, Uehara A, Ogino S, Torii R, Ishikawa O and Motegi SI:
Inhibitory regulation of skin fibrosis in systemic sclerosis by
apelin/APJ signaling. Arthritis Rheumatol. 70:1661–1672. 2018.
|
|
19
|
Wang LY, Diao ZL, Zhang DL, Zheng JF,
Zhang QD, Ding JX and Liu WH: The regulatory peptide apelin: A
novel inhibitor of renal interstitial fibrosis. Amino Acids.
46:2693–2704. 2014.
|
|
20
|
Picault FX, Chaves-Almagro C, Projetti F,
Prats H, Masri B and Audigier Y: Tumour co-expression of apelin and
its receptor is the basis of an autocrine loop involved in the
growth of colon adenocarcinomas. Eur J Cancer. 50:663–674.
2014.
|
|
21
|
Zuurbier L, Rahman A, Cordes M, Scheick J,
Wong TJ, Rustenburg F, Joseph JC, Dynoodt P, Casey R, Drillenburg
P, et al: Apelin: A putative novel predictive biomarker for
bevacizumab response in colorectal cancer. Oncotarget.
8:42949–42961. 2017.
|
|
22
|
Chen T, Liu N, Xu GM, Liu TJ, Liu Y, Zhou
Y, Huo SB and Zhang K: Apelin13/APJ promotes proliferation of colon
carcinoma by activating notch3 signaling pathway. Oncotarget.
8:101697–101706. 2017.
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
|
|
24
|
Wang P, Liang J, Wang Z, Hou H, Shi L and
Zhou Z: The prognostic value of p53 positive in colorectal cancer:
A retrospective cohort study. Tumour Biol.
39:10104283177036512017.
|
|
25
|
Trivedi M, Talekar M, Shah P, Ouyang Q and
Amiji M: Modification of tumor cell exosome content by transfection
with wt-p53 and microRNA-125b expressing plasmid DNA and its effect
on macrophage polarization. Oncogenesis. 5:e2502016.
|
|
26
|
Cooks T, Pateras IS, Jenkins LM, Patel KM,
Robles AI, Morris J, Forshew T, Appella E, Gorgoulis VG and Harris
CC: Mutant p53 cancers reprogram macrophages to tumor-supporting
macrophages via exosomal miR-1246. Nat Commun. 9:7712018.
|
|
27
|
Shen J, Feng J, Wu Z, Ou Y, Zhang Q, Nong
Q, Wu Q, Li C, Tan X, Ye M, et al: Apelin prevents and alleviates
crystalline silica-induced pulmonary fibrosis via inhibiting
transforming growth factor beta 1-triggered fibroblast activation.
Int J Biol Sci. 19:4004–4019. 2023.
|
|
28
|
Wang LY, Diao ZL, Zheng JF, Wu YR, Zhang
QD and Liu WH: Apelin attenuates TGF-β1-induced epithelial to
mesenchymal transition via activation of PKC-ε in human renal
tubular epithelial cells. Peptides. 96:44–52. 2017.
|
|
29
|
Guinney J, Dienstmann R, Wang X, Reynies
A, Schlicker A, Soneson C, Marisa L, Roepman P, Nyamundanda G,
Angelino P, et al: The consensus molecular subtypes of colorectal
cancer. Nat Med. 21:1350–1356. 2015.
|
|
30
|
Neelakantan D, Dogra S, Devapatla B,
Jaiprasart P, Mukashyaka MC, Janknecht R, Dwivedi SK, Bhattacharya
R, Husain S, Ding K and Woo S: Multifunctional APJ pathway promotes
ovarian cancer progression and metastasis. Mol Cancer Res.
17:1378–1390. 2019.
|
|
31
|
Podgórska M, Diakowska D,
Pietraszek-Gremplewicz K, Nienartowicz M and Nowak D: Evaluation of
apelin and apelin receptor level in the primary tumor and serum of
colorectal cancer patients. J Clin Med. 8:15132019.
|
|
32
|
Hu D, Cui Z, Peng W, Wang X, Chen Y and Wu
X: Apelin is associated with clinicopathological parameters and
prognosis in breast cancer patients. Arch Gynecol Obstet.
306:1185–1195. 2022.
|
|
33
|
Yusha C, Lin X, Zheng J, Chen J, Xue H and
Zheng X: APLN: A potential novel biomarker for cervical cancer. Sci
Prog. 104:3685042110113412021.
|
|
34
|
Hall C, Ehrlich L, Venter J, O'Brien A,
White T, Zhou T, Dang T, Meng F, Invernizzi P, Bernuzzi F, et al:
Inhibition of the apelin/apelin receptor axis decreases
cholangiocarcinoma growth. Cancer Lett. 386:179–188. 2017.
|
|
35
|
Kosaka N, Yoshioka Y, Fujita Y and Ochiya
T: Versatile roles of extracellular vesicles in cancer. J Clin
Invest. 126:1163–1172. 2016.
|
|
36
|
Valadi H, Ekström K, Bossios A, Sjöstrand
M, Lee JJ and Lötvall JO: Exosome-mediated transfer of mRNAs and
microRNAs is a novel mechanism of genetic exchange between cells.
Nat Cell Biol. 9:654–659. 2007.
|
|
37
|
Zhang Y, Liu D, Chen X, Li J, Li L, Bian
Z, Sun F, Lu J, Yin Y, Cai X, et al: Secreted monocytic miR-150
enhances targeted endothelial cell migration. Mol Cell. 39:133–144.
2010.
|
|
38
|
Pranavkrishna S, Sanjeev G, Akshaya RL,
Rohini M and Selvamurugan N: A computational approach on studying
the regulation of TGF-β1-stimulated Runx2 expression by microRNAs
in human breast cancer cells. Comput Biol Med. 137:1048232021.
|
